Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Duc Bui Minh is active.

Publication


Featured researches published by Duc Bui Minh.


Journal of Experimental Medicine | 2008

Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies

Carmen Giefing; Andreas Meinke; Markus Hanner; Tamás Henics; Duc Bui Minh; Dieter Gelbmann; Urban Lundberg; Beatrice Senn; Michael Schunn; André Habel; Birgitta Henriques-Normark; Åke Örtqvist; Mats Kalin; Alexander von Gabain; Eszter Nagy

Pneumococcus is one of the most important human pathogens that causes life-threatening invasive diseases, especially at the extremities of age. Capsular polysaccharides (CPSs) are known to induce protective antibodies; however, it is not feasible to develop CPS-based vaccines that cover all of the 90 disease-causing serotypes. We applied a genomic approach and described the antibody repertoire for pneumococcal proteins using display libraries expressing 15–150 amino acid fragments of the pathogens proteome. Serum antibodies of exposed, but not infected, individuals and convalescing patients identified the ANTIGENome of pneumococcus consisting of ∼140 antigens, many of them surface exposed. Based on several in vitro assays, 18 novel candidates were preselected for animal studies, and 4 of them showed significant protection against lethal sepsis. Two lead vaccine candidates, protein required for cell wall separation of group B streptococcus (PcsB) and serine/threonine protein kinase (StkP), were found to be exceptionally conserved among clinical isolates (>99.5% identity) and cross-protective against four different serotypes in lethal sepsis and pneumonia models, and have important nonredundant functions in bacterial multiplication based on gene deletion studies. We describe for the first time opsonophagocytic killing activity for pneumococcal protein antigens. A vaccine containing PcsB and StkP is intended for the prevention of infections caused by all serotypes of pneumococcus in the elderly and in children.


Proceedings of the National Academy of Sciences of the United States of America | 2002

Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus

Hildegard Etz; Duc Bui Minh; Tamás Henics; Agnieszka Dryla; Birgit Winkler; Christine Triska; Aoife P. Boyd; Johannes Söllner; Walter Schmidt; Uwe von Ahsen; Michael Buschle; Steven R. Gill; James F. Kolonay; Hanif G. Khalak; Claire M. Fraser; Alexander von Gabain; Eszter Nagy; Andreas Meinke

For the design of potent subunit vaccines, it is of paramount importance to identify all antigens immunologically recognized by a patient population infected with a pathogen. We have developed a rapid and efficient procedure to identify such commonly recognized antigens, and here we provide a comprehensive in vivo antigenic profile of Staphylococcus aureus, an important human pathogen. S. aureus peptides were displayed on the surface of Escherichia coli via fusion to one of two outer membrane proteins (LamB and FhuA) and probed with sera selected for high Ab titer and opsonic activity. A total of 60 antigenic proteins were identified, most of which are located or predicted to be located on the surface of the bacterium or secreted. The identification of these antigens and their reactivity with individual sera from patients and healthy individuals greatly facilitate the selection of promising vaccine candidates for further evaluation. This approach, which makes use of whole genome sequence information, has the potential to greatly accelerate and facilitate the formulation of novel vaccines and is applicable to any pathogen that induces Abs in humans and/or experimental animals.


Infection and Immunity | 2010

Novel conserved group A streptococcal proteins identified by the antigenome technology as vaccine candidates for a non-M protein-based vaccine.

Andrea Fritzer; Beatrice Senn; Duc Bui Minh; Markus Hanner; Dieter Gelbmann; Birgit Noiges; Tamás Henics; Kai Schulze; Carlos A. Guzmán; John Goodacre; Alexander von Gabain; Eszter Nagy; Andreas Meinke

ABSTRACT Group A streptococci (GAS) can cause a wide variety of human infections ranging from asymptomatic colonization to life-threatening invasive diseases. Although antibiotic treatment is very effective, when left untreated, Streptococcus pyogenes infections can lead to poststreptococcal sequelae and severe disease causing significant morbidity and mortality worldwide. To aid the development of a non-M protein-based prophylactic vaccine for the prevention of group A streptococcal infections, we identified novel immunogenic proteins using genomic surface display libraries and human serum antibodies from donors exposed to or infected by S. pyogenes. Vaccine candidate antigens were further selected based on animal protection in murine lethal-sepsis models with intranasal or intravenous challenge with two different M serotype strains. The nine protective antigens identified are highly conserved; eight of them show more than 97% sequence identity in 13 published genomes as well as in approximately 50 clinical isolates tested. Since the functions of the selected vaccine candidates are largely unknown, we generated deletion mutants for three of the protective antigens and observed that deletion of the gene encoding Spy1536 drastically reduced binding of GAS cells to host extracellular matrix proteins, due to reduced surface expression of GAS proteins such as Spy0269 and M protein. The protective, highly conserved antigens identified in this study are promising candidates for the development of an M-type-independent, protein-based vaccine to prevent infection by S. pyogenes.


Journal of Bacteriology | 2001

Bacterial Phage Receptors, Versatile Tools for Display of Polypeptides on the Cell Surface

Hildegard Etz; Duc Bui Minh; Carola Schellack; Eszter Nagy; Andreas Meinke

Four outer membrane proteins of Escherichia coli were examined for their capabilities and limitations in displaying heterologous peptide inserts on the bacterial cell surface. The T7 tag or multiple copies of the myc epitope were inserted into loops 4 and 5 of the ferrichrome and phage T5 receptor FhuA. Fluorescence-activated cell sorting analysis showed that peptides of up to 250 amino acids were efficiently displayed on the surface of E. coli as inserts within FhuA. Strains expressing FhuA fusion proteins behaved similarly to those expressing wild-type FhuA, as judged by phage infection and colicin sensitivity. The vitamin B(12) and phage BF23 receptor BtuB could display peptide inserts of at least 86 amino acids containing the T7 tag. In contrast, the receptors of the phages K3 and lambda, OmpA and LamB, accepted only insertions in their respective loop 4 of up to 40 amino acids containing the T7 tag. The insertion of larger fragments resulted in inefficient transport and/or assembly of OmpA and LamB fusion proteins into the outer membrane. Cells displaying a foreign peptide fused to any one of these outer membrane proteins were almost completely recovered by magnetic cell sorting from a large pool of cells expressing the relevant wild-type platform protein only. Thus, this approach offers a fast and simple screening procedure for cells displaying heterologous polypeptides. The combination of FhuA, along with with BtuB and LamB, should provide a comprehensive tool for displaying complex peptide libraries of various insert sizes on the surface of E. coli for diverse applications.


Vaccine | 2010

Immunological fingerprinting of group B streptococci: from circulating human antibodies to protective antigens.

Andreas Meinke; Beatrice Senn; Zehra Visram; Tamás Henics; Duc Bui Minh; Wolfgang Schüler; Christina Neubauer; Dieter Gelbmann; Birgit Noiges; Jan Sinzinger; Markus Hanner; Shailesh Dewasthaly; Urban Lundberg; Knut Hordnes; Helga Masoud; Paul Sevelda; Alexander von Gabain; Eszter Nagy

Group B streptococcus is one of the most important pathogens in neonates, and causes invasive infections in non-pregnant adults with underlying diseases. Applying a genomic approach that relies on human antibodies we identified antigenic GBS proteins, among them most of the previously published protective antigens. In vitro analyses allowed the selection of conserved candidate antigens that were further evaluated in murine lethal sepsis models using several GBS strains. In active and passive immunization models, we identified four protective GBS antigens, FbsA and BibA, as well as two hypothetical proteins, all shown to contribute to virulence based on gene deletion mutants. These protective antigens have the potential to be components of novel vaccines or targets for passive immune prophylaxis against GBS disease.


Vaccine | 2009

Composition of the ANTIGENome of Helicobacter pylori defined by human serum antibodies

Andreas Meinke; Martin Storm; Tamás Henics; Dieter Gelbmann; Sonja Prustomersky; Zoltán Kovács; Duc Bui Minh; Birgit Noiges; Ulrike Stierschneider; Manfred Berger; Alexander von Gabain; Lars Engstrand; Eszter Nagy

Helicobacter pylori is the most prevalent human pathogen and although, it remains silent in most individuals for lifetime, colonization may develop into severe gastric and duodenal conditions. Rapidly developing resistance to antibiotic treatment urgently calls for the development of effective vaccines. We determined the ANTIGENome of two clinical isolates of H. pylori, KTH-Ca1 and KTH-Du, derived from patients with gastric cancer and duodenal ulcer, respectively. Using disease-relevant human sera from well-characterized donors we identified 124 annotated ORFs and 54 non-annotated peptides as antigens. Through in vitro validation assays we selected the 20 most promising vaccine candidates. Importantly, two candidates represent proteins that were previously shown to provide protection in models of H. pylori infection. One of the most frequently selected and conserved protein, the siderophore-dependent transporter HP1341, was confirmed to show high reactivity with human serum IgGs. These analyses provide the means to identify novel antigens for the selection of vaccine candidates, as well as disease associated biomarkers.


Archive | 2002

A method for identification, isolation and production of antigens to a specific pathogen

Andreas Meinke; Eszter Nagy; Ahsen Uwe Von; Christoph Klade; Tamás Henics; Wolfgang Zauner; Duc Bui Minh; Oresta Vytvytska; Hildegard Etz; Agnieszka Dryla; Thomas Weichhart; Martin Hafner; Brigitte Tempelmaier; Claire M. Fraser; Steven Gill


Vaccine | 2005

Antigenome technology : a novel approach for the selection of bacterial vaccine candidate antigens

Andreas Meinke; Tamás Henics; Markus Hanner; Duc Bui Minh; Eszter Nagy


Zeitschrift Fur Gastroenterologie | 2010

Antigenome of Helicobacter pylori: vaccination on the horizon?

Z Kovács; Andreas Meinke; Eszter Nagy; Tamás Henics; Dieter Gelbmann; Sonja Prustomersky; Duc Bui Minh; Birgit Winkler; Ulrike Stierschneider; Manfred Berger; A von Gabain; Martin Storm; Lars Engstrand; B Hunyady


Archive | 2002

Procedure for the identification, isolation and production of antigens to a specific pathogen.

Agnieszka Dryla; Hildegard Etz; Claire M. Fraser; Steven Gill; Martin Hafner; Tamás Henics; Christoph Klade; Andreas Meinke; Duc Bui Minh; Eszter Nagy; Brigitte Tempelmaier; Ahsen Uwe; Von; Oresta Vytvytska; Thomas Weichhart; Wolfgang Zauner

Collaboration


Dive into the Duc Bui Minh's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Eszter Nagy

Roswell Park Cancer Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Tamás Henics

Roswell Park Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Tamás Henics

Roswell Park Cancer Institute

View shared research outputs
Researchain Logo
Decentralizing Knowledge